Project Grant R44AI142948

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, provides $709,236 to support research aimed at overcoming immunodominance to enable the development of universal influenza vaccines. The primary goal is to gain mechanistic insights into how adjuvant formulation influences B cell intrinsic and extrinsic factors that shape immunodominance and the breadth of humoral responses....

This Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to investigate the role of monocyte-derived galectin-1 in promoting tissue-resident memory T cell responses against influenza infections. The $722,958 award, made on November 22, 2024, will fund the University of Rochester's research to: Examine monocyte differentiation and the formation of memory T cells after...

The federal Project Grant award R44AI186932 for $300,000 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award supports the development of an "Enhanced Seasonal Influenza Vaccine Targeting Variable and Conserved Antigens" by Orlance, Inc., a woman-owned small business. The project aims to combine the advantages of a closely matched seasonal influenza DNA vaccine with a...

This Cooperative Agreement award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $1,195,056 to Vanderbilt University to develop and implement computational tools to design broadly protective influenza vaccines. The project aims to leverage machine learning and artificial intelligence to create innovative immunogen candidates that can overcome the limitations of current influenza vaccines...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a 5-year, $1,082,429 Cooperative Agreement to Duke University to develop computational models that predict the sequences of antibody archetypes generated in response to influenza proteins and simulate how a polyclonal antibody response protects against influenza infection. The research aims to address the challenges of seasonal influenza vaccines, which have only 10-60% effectiveness, and the potential for devastating...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to investigate factors that enhance the protective capacity of antibodies through Fc-mediated immune responses. The $416,276 award to the University of Georgia Research Foundation will fund research to quantify how factors like epitope location, antibody glycosylation, and oligomerization affect the potency of...

The University of Missouri System, under a $650,000 project grant from the USDA National Institute of Food and Agriculture (NIFA) Agriculture and Food Research Initiative (AFRI) program, is developing safe and effective live attenuated swine influenza vaccines using Newcastle disease virus (NDV) as the vector. The project aims to address the challenges with current swine influenza vaccines, which often fail to provide cross-protection against diverse virus strains. The key products and...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is focused on understanding how antigen duration and vaccine construct modulate the infant immune response to influenza vaccines. The $456,390 award, made on March 21, 2025, supports research to explore a prolonged antigen delivery approach for nanoparticle-based influenza vaccines in infants. Key findings indicate that this...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $230,000 project grant (R21AI185735) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute. The grant supports research focused on developing a broad-spectrum influenza vaccine by targeting the neuraminidase (NA) protein. Specifically, the project aims to evaluate recently discovered NA broadly neutralizing antibodies (bnAbs) to assess their potential for...

This $586,250 Project Grant award was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The funding supports research to investigate how distinct age-associated B cell subsets can protect the aged population from influenza. The primary focus is on understanding the potential of "age-associated B cells" (ABC) to respond to influenza infection and generate antibody-secreting cells, B...